8 protocols meet the specified criteria

OCR13631

Molecular Analysis for Therapy Choice (MATCH)

OCR15732

Phase II Trial of the PARP1 Inhibitor, Niraparib, in BAP1 and other DNA Damage Response (DDR) Pathway Deficient Neoplasms (UF-STO-ETI-001)

OCR16016

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

OCR17458

Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors (SGNTV-001)

OCR18241

A Randomized, Double-Blind, Phase 3 Comparison of Platinum-Based Therapy with Tsr-042 and Niraparib versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III Or IV Nonmucinous Epithelial Ovarian Cancer

OCR18617

A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors

OCR19140

Phase 1 Dose Escalation and Randomized Phase 2 Trial of Carboplatin and Gemcitabine With or Without VX-970 in First Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube Cancer

OCR20077

A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer